ReviewCancer cell2015
Emerging strategies for treating brain metastases from breast cancer.
Review in Cancer cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed.
- Targetable S100-RAGE Signaling Mediates Intrinsic Trastuzumab Deruxtecan Resistance in Metastatic Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Article
- Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis.Cancer research · 2026Article
- Breast cancer brain metastasis: from molecular insights to therapeutic innovation.Frontiers in immunology · 2026Review
- Biological profile of breast cancer brain metastasis.Acta neuropathologica communications · 2025Review
- Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer.Cancers · 2024Review
- Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- SRRM4-mediated REST to REST4 dysregulation promotes tumor growth and neural adaptation in breast cancer leading to brain metastasis.Neuro-oncology · 2024Article
- Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases.The Journal of clinical investigation · 2023Article
- Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2-positive cancers.Molecular oncology · 2023Article
- SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models.Breast cancer research : BCR · 2023Article
- AnHeliyon · 2022Article
- Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors.Biomedicines · 2022Review
- Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments.Nature communications · 2022Article
- Recapitulated Crosstalk between Cerebral Metastatic Lung Cancer Cells and Brain Perivascular Tumor Microenvironment in a Microfluidic Co-Culture Chip.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Identification of Key Genes Associated with Brain Metastasis from Breast Cancer: A Bioinformatics Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancerActa pharmaceutica Sinica. B · 2022Article
- Article
- Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness.Cell metabolism · 2022Article
- Sortilin-related receptor is a druggable therapeutic target in breast cancer.Molecular oncology · 2022Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Brain metastasis is an end stage in breast cancer progression. Traditional treatment options have minimal efficacy, and overall survival is on the order of months. The incidence of brain metastatic disease is increasing with the improved management of systemic disease and prolongation of survival. Unfortunately, the targeted therapies that control systemic disease have diminished efficacy against brain lesions. There are reasons to be optimistic, however, as emerging therapies have shown promise in preclinical and early clinical settings. This review discusses recent advances in breast cancer brain metastasis therapy and potential approaches for successful treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.